Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10874668-B2
Publication Date
2020-12-29
Expiration Date
Abstract
The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.
Core Innovation
The invention relates to pharmaceutical composition(s) and methods for treatment and/or prevention of obesity and related disorders using flibanserin. Flibanserin is described in forms including flibanserin free base, pharmaceutically acceptable acid addition salts, hydrates, solvates, and flibanserin polymorph A.
The document states that flibanserin shows mechanisms through affinity to the 5-HT1A and 5-HT2 receptor family. Therapeutic outcomes described include facilitating weight loss, reducing appetite, and addressing metabolic comorbidities associated with obesity and related disorders.
The invention further describes co-administration and combination of flibanserin with one or more non-flibanserin anti-obesity or related-disease active substances. Non-flibanserin active substances explicitly mentioned include orlistat, sibutramine, phentermine, topiramate, and agents for diabetes, hypertension, dyslipidaemia, arthritis, and other referenced conditions.
Claims Coverage
The independent claim coverage centers on a pharmaceutical composition suitable for oral administration that combines flibanserin with a specified set of non-flibanserin active substances, with optional flibanserin salt/hydrate/solvate forms. One independent claim is identified in the provided content.
Oral pharmaceutical composition combining non-flibanserin anti-obesity actives with flibanserin
A pharmaceutical composition in a form suitable for oral administration, comprising an active substance being not flibanserin and selected from orlistat, phentermine, sibutramine, and topiramate (or pharmaceutically acceptable salts thereof) together with flibanserin, optionally as free base and/or as pharmaceutically acceptable acid addition salts, and optionally as hydrates and/or solvates.
The provided independent claim is directed to an oral pharmaceutical composition that includes flibanserin, optionally as free base and/or pharmaceutically acceptable acid addition salts, hydrates, and/or solvates, combined with a non-flibanserin active substance selected from orlistat, phentermine, sibutramine, and topiramate or their pharmaceutically acceptable salts.
Stated Advantages
Facilitates weight loss.
Reduces appetite.
Addresses metabolic comorbidities associated with obesity and related disorders.
Prevents body weight gain.
Documented Applications
Treatment and/or prevention of obesity, including BMI-based definitions and obesity subtypes.
Treatment and/or prevention of obesity-related disorders and metabolic comorbidities, including metabolic syndrome (syndrome X).
Treatment and/or prevention of diabetes and diabetic complications, insulin resistance, dyslipidaemia, arteriosclerosis, hypertension, osteoarthritis, and arthritis as obesity-related conditions referenced in the document.
Co-administration and combination of flibanserin with non-flibanserin anti-obesity or related-disease active substances, including kit concepts.
Interested in licensing this patent?